Author: Ned Pagliarulo

Amgen, Merck and Eli Lilly successfully blocked the rule from taking effect in July, winning a district court decision that HHS is now appealing.  Source: Healthcare Dive, https://www.healthcaredive.com

UnitedHealthcare will preferentially cover lower-cost versions of Roche's top-selling cancer drugs, helping Amgen's efforts to gain market share.  Source: Healthcare Dive, https://www.healthcaredive.com

CMS also broadened the settings in which the pricey therapies would be covered, applying its final rule to use in "healthcare facilities" rather than explicitly in hospitals. Source: Healthcare Dive, https://www.healthcaredive.com